June 13, 2018 / 12:47 AM / in 7 days

BTG owes Wellstat $55.8 mln in drug contract dispute: Delaware top court

The Delaware Supreme Court has upheld a decision requiring British pharmaceutical company BTG Plc to pay $55.8 million plus interest to Wellstat Therapeutics Corp for failing to properly market the latter’s chemotherapy overexposure antidote.

The top Delaware court largely affirmed a ruling in September by Vice Chancellor Travis Laster, who found BTG breached a distribution contract for Wellstat’s Vistogard by failing to prepare in good faith a plan to commercialize the drug and then failing to market it in accordance with the plan.

To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2l6SkwO

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below